Bimzelx UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
Product name
Bimzelx
Accepted date
Apr-2024
Active ingredients
bimekizumab
Proposed indication
For the treatment of adult patients with moderate to severe hidradenitis suppurativa.
Application type
C (new indication)
Publication date
Apr-2024